ArticleBMJ open2026
Comparing ovulation induction strategies for unexplained infertility: protocol for a systematic review and network meta-analysis.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionUnexplained infertility affects about 30% of couples seeking help for infertility, yet the optimal ovulation induction strategy remains largely unclear. Letrozole, clomiphene citrate and gonadotropins are widely used, alone or in combination, with or without intrauterine insemination (IUI), but evidence of comparative effectiveness and safety is inconsistent. Most reviews are restricted to pairwise comparisons or mixed infertility populations. This protocol describes a systematic review and network meta-analysis (NMA) to compare ovulation induction strategies specifically in unexplained infertility. METHODS AND ANALYSIS: Parallel-group randomised controlled trials (RCTs), including women aged 18-40 years with unexplained infertility, will be eligible. Interventions include letrozole, clomiphene citrate, gonadotropins, combination regimens and expectant management/ placebo, with or without IUI. The primary outcome will be live birth per woman randomised; if unavailable, ongoing or clinical pregnancy will be considered. Secondary outcomes include ovulation, multiple pregnancy, miscarriage, ovarian hyperstimulation syndrome, ectopic pregnancy, neonatal outcomes, time to pregnancy, adverse events and cycle cancellation rates. Databases (MEDLINE/PubMed, Embase, Cochrane Library, Scopus and Web of Science), trial registry (ClinicalTrials.gov), and grey literature (postgraduate theses, conference abstracts and dissertations) will be searched from inception to September 2025. Two reviewers will independently screen, extract data and assess risk of bias (RoB-2). Pairwise random-effects meta-analyses will precede a Bayesian and frequentist NMA (if sufficient network). If feasible, component NMA will be performed to estimate marginal effects of drug and procedural components. Certainty of evidence will be assessed using the CINeMA framework (GRADE for NMA). Publication bias will be assessed using funnel plots and Egger's test, where feasible. ETHICS AND DISSEMINATION: No ethics approval is required. Findings will be published in peer-reviewed journals, presented at conferences and made available through open-access repositories. PROSPERO REGISTRATION NUMBER: CRD420251145492. The review was registered prospectively; the review start date is 11 September 2025 and the anticipated end date is 3 March 2026.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.